Synergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo

Fei Ting Hsu, Betty Chang, John Chun Hao Chen, I. Tsang Chiang, Yu Chang Liu, Wei Kang Kwang, Jeng Jong Hwang

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Oral squamous cell carcinoma often causes bone invasion resulting in poor prognosis and affects the quality of life for patients. Herein, we combined radiation with sorafenib, to evaluate the combination effect on tumor progression and bone erosion in an in situ human OSCC-bearing mouse model. Treatment procedure were arranged as following groups: (a) normal (no tumor); (b) control (with tumor); (c) sorafenib (10 mg/kg/day); (d) radiation (single dose of 6 Gy); (e) pretreatment (sorafenib treatment for 3 days prior to radiation), and (f) concurrent treatment (sorafenib and radiation on the same day). The inhibition of tumor growth and expression level of p65 of NF-κB in tumor tissues were the most significant in the pretreatment group. EMSA and Western blot showed that DNA/NF-κB activity and the expressions of NF-κB-associated proteins were downregulated. Notably, little to no damage in mandibles and zygomas of mice treated with combination of sorafenib and radiation was found by micro-CT imaging. In conclusion, sorafenib combined with radiation suppresses radiation-induced NF-κB activity and its downstream proteins, which contribute to radioresistance and tumorigenesis. Additionally, bone destruction is also diminished, suggesting that combination treatment could be a potential strategy against human OSCC.

Original languageEnglish
Article number15391
JournalScientific Reports
Volume5
DOIs
Publication statusPublished - Oct 21 2015
Externally publishedYes

Fingerprint

Radiation Effects
Radiation
Carcinoma
Neoplasms
Bone and Bones
Therapeutics
sorafenib
Mandible
Squamous Cell Carcinoma
Carcinogenesis
Down-Regulation
Western Blotting
Quality of Life
DNA
Growth
Proteins

ASJC Scopus subject areas

  • General

Cite this

Hsu, F. T., Chang, B., Chen, J. C. H., Chiang, I. T., Liu, Y. C., Kwang, W. K., & Hwang, J. J. (2015). Synergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo. Scientific Reports, 5, [15391]. https://doi.org/10.1038/srep15391

Synergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo. / Hsu, Fei Ting; Chang, Betty; Chen, John Chun Hao; Chiang, I. Tsang; Liu, Yu Chang; Kwang, Wei Kang; Hwang, Jeng Jong.

In: Scientific Reports, Vol. 5, 15391, 21.10.2015.

Research output: Contribution to journalArticle

Hsu, FT, Chang, B, Chen, JCH, Chiang, IT, Liu, YC, Kwang, WK & Hwang, JJ 2015, 'Synergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo', Scientific Reports, vol. 5, 15391. https://doi.org/10.1038/srep15391
Hsu FT, Chang B, Chen JCH, Chiang IT, Liu YC, Kwang WK et al. Synergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo. Scientific Reports. 2015 Oct 21;5. 15391. https://doi.org/10.1038/srep15391
Hsu, Fei Ting ; Chang, Betty ; Chen, John Chun Hao ; Chiang, I. Tsang ; Liu, Yu Chang ; Kwang, Wei Kang ; Hwang, Jeng Jong. / Synergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo. In: Scientific Reports. 2015 ; Vol. 5.
@article{0c23ecaeecd04229865edfca701239a5,
title = "Synergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo",
abstract = "Oral squamous cell carcinoma often causes bone invasion resulting in poor prognosis and affects the quality of life for patients. Herein, we combined radiation with sorafenib, to evaluate the combination effect on tumor progression and bone erosion in an in situ human OSCC-bearing mouse model. Treatment procedure were arranged as following groups: (a) normal (no tumor); (b) control (with tumor); (c) sorafenib (10 mg/kg/day); (d) radiation (single dose of 6 Gy); (e) pretreatment (sorafenib treatment for 3 days prior to radiation), and (f) concurrent treatment (sorafenib and radiation on the same day). The inhibition of tumor growth and expression level of p65 of NF-κB in tumor tissues were the most significant in the pretreatment group. EMSA and Western blot showed that DNA/NF-κB activity and the expressions of NF-κB-associated proteins were downregulated. Notably, little to no damage in mandibles and zygomas of mice treated with combination of sorafenib and radiation was found by micro-CT imaging. In conclusion, sorafenib combined with radiation suppresses radiation-induced NF-κB activity and its downstream proteins, which contribute to radioresistance and tumorigenesis. Additionally, bone destruction is also diminished, suggesting that combination treatment could be a potential strategy against human OSCC.",
author = "Hsu, {Fei Ting} and Betty Chang and Chen, {John Chun Hao} and Chiang, {I. Tsang} and Liu, {Yu Chang} and Kwang, {Wei Kang} and Hwang, {Jeng Jong}",
year = "2015",
month = "10",
day = "21",
doi = "10.1038/srep15391",
language = "English",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Synergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo

AU - Hsu, Fei Ting

AU - Chang, Betty

AU - Chen, John Chun Hao

AU - Chiang, I. Tsang

AU - Liu, Yu Chang

AU - Kwang, Wei Kang

AU - Hwang, Jeng Jong

PY - 2015/10/21

Y1 - 2015/10/21

N2 - Oral squamous cell carcinoma often causes bone invasion resulting in poor prognosis and affects the quality of life for patients. Herein, we combined radiation with sorafenib, to evaluate the combination effect on tumor progression and bone erosion in an in situ human OSCC-bearing mouse model. Treatment procedure were arranged as following groups: (a) normal (no tumor); (b) control (with tumor); (c) sorafenib (10 mg/kg/day); (d) radiation (single dose of 6 Gy); (e) pretreatment (sorafenib treatment for 3 days prior to radiation), and (f) concurrent treatment (sorafenib and radiation on the same day). The inhibition of tumor growth and expression level of p65 of NF-κB in tumor tissues were the most significant in the pretreatment group. EMSA and Western blot showed that DNA/NF-κB activity and the expressions of NF-κB-associated proteins were downregulated. Notably, little to no damage in mandibles and zygomas of mice treated with combination of sorafenib and radiation was found by micro-CT imaging. In conclusion, sorafenib combined with radiation suppresses radiation-induced NF-κB activity and its downstream proteins, which contribute to radioresistance and tumorigenesis. Additionally, bone destruction is also diminished, suggesting that combination treatment could be a potential strategy against human OSCC.

AB - Oral squamous cell carcinoma often causes bone invasion resulting in poor prognosis and affects the quality of life for patients. Herein, we combined radiation with sorafenib, to evaluate the combination effect on tumor progression and bone erosion in an in situ human OSCC-bearing mouse model. Treatment procedure were arranged as following groups: (a) normal (no tumor); (b) control (with tumor); (c) sorafenib (10 mg/kg/day); (d) radiation (single dose of 6 Gy); (e) pretreatment (sorafenib treatment for 3 days prior to radiation), and (f) concurrent treatment (sorafenib and radiation on the same day). The inhibition of tumor growth and expression level of p65 of NF-κB in tumor tissues were the most significant in the pretreatment group. EMSA and Western blot showed that DNA/NF-κB activity and the expressions of NF-κB-associated proteins were downregulated. Notably, little to no damage in mandibles and zygomas of mice treated with combination of sorafenib and radiation was found by micro-CT imaging. In conclusion, sorafenib combined with radiation suppresses radiation-induced NF-κB activity and its downstream proteins, which contribute to radioresistance and tumorigenesis. Additionally, bone destruction is also diminished, suggesting that combination treatment could be a potential strategy against human OSCC.

UR - http://www.scopus.com/inward/record.url?scp=84944916681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944916681&partnerID=8YFLogxK

U2 - 10.1038/srep15391

DO - 10.1038/srep15391

M3 - Article

AN - SCOPUS:84944916681

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 15391

ER -